PD-1 Non-Small Cell Lung Cancer Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

DelveInsight "PD-1 Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the PD-1 Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the PD-1 Non-Small Cell Lung Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover which therapies are expected to grab the PD-1 Non-Small Cell Lung Cancer Market Share @ PD-1 Non-Small Cell Lung Cancer Market Outlook [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the PD-1 Non-Small Cell Lung Cancer Market Report

* In April 2025, Merck Sharp & Dohme LLC announced a phase 2 umbrella study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC).
* In April 2025, Sichuan Baili Pharmaceutical Co., Ltd. announced a phase III clinical study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer After Failure of Anti-PD-1/PD-L1 Monoclonal Antibodies and Platinum-based Chemotherapy
* The total number of incident cases of NSCLC in the 7MM was nearly 524,000 cases in 2023 and is projected to increase during the forecasted period.
* In 2023, the incidence of NSCLC cases in the United States was~56% in males and~ 44% in females.
* In 2023, the total number of cases of NSCLC in EU4 and the UK was estimated to be nearly 203,220. Among EU4 and the UK, the highest number of cases of NSCLC was found in Germany.
* The biomarker testing rate for PD-(L)1 in the US is around 85%. In Japan, the PD-(L)1 testing rate is more compared to EU4 and the UK.
* The total number of PD-(L)1 NSCLC cases in the US was nearly 101,300 in 2023.
* The increase in PD-1 Non-Small Cell Lung Cancer Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
* As per DelveInsight analysis, the PD-1 Non-Small Cell Lung Cancer Market is anticipated to witness growth at a considerable CAGR.
* The leading PD-1 Non-Small Cell Lung Cancer Companies such as Regeneron Pharmaceuticals, Sanofi, Bavarian Nordic, Sichuan University, Chengdu MedGenCell Co. Ltd., Merck Sharp & Dohme LLC, Dynavax Technologies Corporation, BeiGene, Tesaro Inc., Bristol-Myers Squibb, and others.
* Promising PD-1 Non-Small Cell Lung Cancer Pipeline Therapies such as AZD2936, Pembrolizumab 200 mg, Cisplatin, Carboplatin, Gemcitabine, Gotistobart, Docetaxel, PF-06801591 and others.

Stay ahead in the PD-1 Non-Small Cell Lung Cancer Therapeutics Market with DelveInsight's Strategic Report @ PD-1 Non-Small Cell Lung Cancer Treatment Market Size [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

PD-1 Non-Small Cell Lung Cancer Epidemiology Segmentation in the 7MM

The epidemiology section of PD-1 Non-Small Cell Lung Cancer offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

* Total Incident Cases of NSCLC
* Gender-specific Cases of NSCLC
* Age-specific Cases of NSCLC
* Total Incident Cases of NSCLC by Histology
* Total Incident Cases of NSCLC by Stage
* Total Cases of NSCLC by Genetic Mutations/Biomarkers

Download the report to understand which factors are driving PD-1 Non-Small Cell Lung Cancer Epidemiology trends @ PD-1 Non-Small Cell Lung Cancer Prevalence [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

PD-1 Non-small Cell Lung Cancer Marketed Drugs

* KEYTRUDA (pembrolizumab): Merck

KEYTRUDA is a PD-1-blocking antibody. It is mainly used for advanced cancers that have spread to other body parts or are not responding to other treatments. In some cancers, it is only given to patients whose tumors produce high protein levels known as PD-(L)1. In NSCLC, it is in combination with pemetrexed and platinum chemotherapy as first-line treatment of patients with metastatic non squamous NSCLC, with no EGFR or ALK genomic tumor aberrations. Combining with carboplatin and either paclitaxel or paclitaxel protein-bound as first-line treatment of patients with metastatic squamous NSCLC. The dominance of KEYTRUDA in the oncology drugs market highlights the success of Merck's commercial tactics and the direction of its R&D department. The department is also tasked with evaluating the efficacy of this blockbuster in combination with drugs such as vibostolimab, quavonlimab, and faveselimab.

* OPDIVO (nivolumab): Bristol-Myers Squibb/Ono Pharmaceutical

OPDIVO by Bristol-Myers Squibb is a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1, with immune checkpoint inhibitory and antineoplastic activities. It is a prescription medicine used to treat people with unresectable or metastatic melanoma, metastatic NSCLC, SCLC, advanced renal cell carcinoma, classical Hodgkin lymphoma, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer and hepatocellular carcinoma.

PD-1 Non-small Cell Lung Cancer Emerging Drugs

* Sugemalimab (CS1001): CStone

Sugemalimab is an investigational anti-PD-(L)1 monoclonal antibody discovered by CStone. In December 2022, EQRx announced the acceptance of the Marketing Authorization Application by the UK's Medicines and Healthcare Products Regulatory Agency for sugemalimab in metastatic NSCLC. The application was based on data from the pivotal Phase III GEMSTONE-302 trial, which assessed sugemalimab in combination with chemotherapy as the first-line treatment of metastatic NSCLC.In May 2023, CStone announced that they would regain rights for developing and commercializing sugemalimab outside Greater China upon terminating the license agreement for sugemalimab between CStone and EQRx. Upon transition completion, CStone will lead the regulatory process for sugemalimab MAA reviews by the EMA and the UK MHRA.

* Datopotamab Deruxtecan: Daiichi Sankyo/AstraZeneca

Datopotamab Deruxtecan (Dato-DXd) is an investigational TROP2-directed ADC. Designed using Daiichi Sankyo's proprietary DXd ADC technology, Datopotamab Deruxtecan is one of five lead ADCs in the oncology pipeline of Daiichi Sankyo and one of the most advanced programs in AstraZeneca's ADC scientific platform.

To learn more about PD-1 Non-Small Cell Lung Cancer treatment guidelines, visit @ PD-1 Non-Small Cell Lung Cancer Treatment Market Landscape [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

PD-1 Non-small Cell Lung Cancer Drugs Market Insights

Checkpoint inhibitors targeting PD-(L)1 have emerged as dominant forces in the immunotherapy landscape for cancer treatment, with ten PD-(L)1 inhibitors approved, comprising seven PD-1 and three PD-L1 inhibitors in the United States. Their efficacy has been notable across various solid tumors, with KEYTRUDA being a standout among these agents, approved for a remarkable twenty indications and holding a significant market presence for several years. However, recent concerns over adverse events have prompted a shift towards combination approaches aimed at enhancing both efficacy and safety. This strategy involves combining PD-(L)1 inhibitors with other checkpoint inhibitors such as CTLA-4, TIGIT, and LAG-3, as well as exploring novel targets like TROP-2. Due to its numerous indication approvals, which led to a comprehensive FDA label and widespread use across a number of indications, PD-1 exceeds the sales of PD-L1 in the 7MM market. Despite their potential, immune checkpoint inhibitors face challenges, including immune-related side effects and high costs, highlighting the critical need for reliable biomarkers to identify patients who would benefit most from these treatments.

PD-1 Non-Small Cell Lung Cancer Market Outlook

Chemotherapy was used as the standard of care in the advanced and metastatic stages until the first ICI 'KEYTRUDA' got approved in 2015 as a second-line treatment option for such advanced patients; a similar path was followed by TECENTRIQ who entered the market in 2016. These therapies entered the first-line domain after 2016 and expanded their labels by expanding the targetable pool. In 2020, OPDIVO + ipilimumab was approved as a 1L treatment for patients with metastatic NSCLC. In the United States, OPDIVO sales are largely fueled by continued demand growth across indications such as NSCLC, melanoma, renal cancer, and upper gastrointestinal cancers. Chinese companies are trying to enter the US and EU markets, especially the EU markets where TIZVENI-approved in 2024 and sugemalimab is currently under review..

Major PD-1 Non-Small Cell Lung Cancer Companies

Regeneron Pharmaceuticals, Sanofi, Bavarian Nordic, Sichuan University, Chengdu MedGenCell Co. Ltd., Merck Sharp & Dohme LLC, Dynavax Technologies Corporation, BeiGene, Tesaro Inc., Bristol-Myers Squibb, and others.

Learn more about the FDA-approved drugs for PD-1 Non-Small Cell Lung Cancer @ Drugs for PD-1 Non-Small Cell Lung Cancer Treatment [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the PD-1 Non-Small Cell Lung Cancer Market Report

- Coverage- 7MM

- Study Period- 2020-2034

- PD-1 Non-Small Cell Lung Cancer Companies- Regeneron Pharmaceuticals, Sanofi, Bavarian Nordic, Sichuan University, Chengdu MedGenCell Co. Ltd., Merck Sharp & Dohme LLC, Dynavax Technologies Corporation, BeiGene, Tesaro Inc., Bristol-Myers Squibb, and others.

- PD-1 Non-Small Cell Lung Cancer Pipeline Therapies- AZD2936, Pembrolizumab 200 mg, Cisplatin, Carboplatin, Gemcitabine, Gotistobart, Docetaxel, PF-06801591 and others.

- PD-1 Non-Small Cell Lung Cancer Market Dynamics: PD-1 Non-Small Cell Lung Cancer Market Drivers and Barriers

- PD-1 Non-Small Cell Lung Cancer Market Access and Reimbursement, Unmet Needs and Future Perspectives

Table of Content

1. Key Insights

2. PD-1 Non-Small Cell Lung Cancer Executive Summary

3. PD-1 Non-Small Cell Lung Cancer Competitive Intelligence Analysis

4. PD-1 Non-Small Cell Lung Cancer: Market Overview at a Glance

5. PD-1 Non-Small Cell Lung Cancer: Disease Background and Overview

6. Patient Journey

7. PD-1 Non-Small Cell Lung Cancer Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. PD-1 Non-Small Cell Lung Cancer Unmet Needs

10. Key Endpoints of PD-1 Non-Small Cell Lung Cancer Treatment

11. PD-1 Non-Small Cell Lung Cancer Marketed Products

12. PD-1 Non-Small Cell Lung Cancer Emerging Therapies

13. PD-1 Non-Small Cell Lung Cancer: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: PD-1 Non-Small Cell Lung Cancer Market Outlook

16. Access and Reimbursement Overview of PD-1 Non-Small Cell Lung Cancer

17. KOL Views

18. PD-1 Non-Small Cell Lung Cancer Market Drivers

19. PD-1 Non-Small Cell Lung Cancer Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pd1-nonsmall-cell-lung-cancer-therapeutics-market-size-in-7mm-is-expected-to-grow-at-a-decent-cagr-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.